A delay in the FDA decision for NT-501 could leave those with macular telangiectasia (MacTel) without any form of treatment for longer than anticipated. Macular telangiectasia (MacTel) type 2 ...

The new PDUFA target date is March 18, 2025. The Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for NT-501 (revakinagene taroretcel ...

Considering taking supplements to treat macular telangiectasia type 2? Below is a list of common natural remedies used to treat or reduce the symptoms of macular telangiectasia type 2. Follow the ...

Arteriovenous malformations, a hallmark of hereditary hemorrhagic telangiectasia ... This revealed that the animals were protected from retinal AVMs, hypervascularization, and vein dilation.